CLINICAL TRIALS PROFILE FOR FOSPHENYTOIN SODIUM
✉ Email this page to a colleague
All Clinical Trials for FOSPHENYTOIN SODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02920060 ↗ | Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus | Completed | Institute of Medical Sciences of the Banaras Hindu University (BHU),India | Phase 2 | 2015-01-01 | This study is a randomized, open label, parallel group,comparing the safety and efficacy of valproate and levetiracetam in patients of age group 1 to 16 years with status epilepticus not responded to phenytoin and benzodiazepines approaching to pediatric emergency , IMS, BHU. The primary outcome measures will be Proportion of children in either group who have Cessation of all clinical seizure within 30 min of drug administration and secondary outcome will be time taken to control seizure (minutes) from the initiation of infusion. Proportion of children in either group who required additional drugs to abort ongoing clinical seizures, rates of adverse events (hypotension, bradycardia, respiratory depression, PICU stay, in hospital mortality) in the two groups were measured. Refractory status epilepticus condition is major pediatric neurological emergency with high mortality and morbidity. Till now, the treatment guidelines for it are based primarily on retrospective studies with very few randomized studies. There is lack of sufficient data to recommend one drug over another for treatment of refractory status epilepticus. |
| NCT02920060 ↗ | Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus | Completed | Banaras Hindu University | Phase 2 | 2015-01-01 | This study is a randomized, open label, parallel group,comparing the safety and efficacy of valproate and levetiracetam in patients of age group 1 to 16 years with status epilepticus not responded to phenytoin and benzodiazepines approaching to pediatric emergency , IMS, BHU. The primary outcome measures will be Proportion of children in either group who have Cessation of all clinical seizure within 30 min of drug administration and secondary outcome will be time taken to control seizure (minutes) from the initiation of infusion. Proportion of children in either group who required additional drugs to abort ongoing clinical seizures, rates of adverse events (hypotension, bradycardia, respiratory depression, PICU stay, in hospital mortality) in the two groups were measured. Refractory status epilepticus condition is major pediatric neurological emergency with high mortality and morbidity. Till now, the treatment guidelines for it are based primarily on retrospective studies with very few randomized studies. There is lack of sufficient data to recommend one drug over another for treatment of refractory status epilepticus. |
| NCT05480553 ↗ | A Phase 3 Study of NPC-06 in Patients With Pain Associated With Acute Herpes Zoster | Not yet recruiting | Nobelpharma | Phase 3 | 2022-08-15 | To confirm the pain relief effect and the safety of NPC-06 (fosphenytoin sodium hydrate) in patients with pain associated with acute herpes zoster in a placebo-controlled, double-blind, parallel-group, comparative manner. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FOSPHENYTOIN SODIUM
Condition Name
Clinical Trial Locations for FOSPHENYTOIN SODIUM
Clinical Trial Progress for FOSPHENYTOIN SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for FOSPHENYTOIN SODIUM
Sponsor Name
